---

$5.90

-0.1050 ( -1.75% ) 441.0K

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-06-16	Buy	25000.00	McCulloch Kevin
2024-08-13	Buy	4515.00	Schmid John P.
2024-08-12	Buy	4285.00	Schmid John P.
2024-08-09	Sale	-3460.00	Pieper Steven
2024-08-09	Sale	-14037.00	Hecht Beth
2024-08-09	Sale	-7497.00	JOHNSON KENNETH ERLAND
2024-08-02	Sale	-150000.00	McCulloch Kevin
2024-08-02	Sale	-250000.00	Shannon John Patrick Jr
2024-06-05	Sale	-50000.00	Kong Garheng
2024-06-05	Sale	-50000.00	Schmid John P.